



Vote of thanks

910-915



High Cancer Risk Population Conference

Focused Targeting in the Era of Precision Oncology 13th & 15th August 2021 * Virtual from Mumbai



Dr Purvish Parikh

"High cancer risk population – focused targeting in the era of precision oncology" 2-day conference - Friday 13th and Sunday 15th August 2021 Under aegis of MOS, IJMIO, ICON, IASCO **Program Director - Dr Uma Dangi** Conference Chairpersons - Dr Sudeep Gupta and Dr Shyam Aggarwal Scientific Chairpersons - Dr Purvish Parikh and Dr Ullas Batra Day 1 - Friday 13th August 2021 - Colorectal and Prostate cancer Welcome Dr Uma Dangi 610-615 Sponsored Session One - Esperer Oncology Nutrition (EON) Nutritional intervention in Colorectal Cancer (CRC) over DINI Axis modulation 615-700 Speaker - Dr Anubhabh Mukherjee 700-710 Welcome, Context Setting and Meeting Objectives Dr Uma Dangi 710-725 Colorectal cancer risk determination – practical considerations Dr Shailesh Bondarde Screening and risk reducing strategies in non-familial high-risk population for 725-740 Dr TP Sahoo **CRC** Screening and Risk reducing strategies in people with familial history of CRC 740-755 Dr Prasad Narayanan Hereditary CRC Case Based Panel Discussion Moderator - Dr Vamshi Krishna 755-825 Panelists - Dr Anant Ramaswamy, Dr Viraj Lavangia, Dr Bharatsingh Bhosale, Dr Sandeep Goyle, Dr Tejinder Singh & Dr MV Chandrakanth Q & A + Chairperson's comments Dr K Govind Babu 825-835 DEBATE - BRCA testing alone vs BRCA and HRR testing for all patients with metastatic prostate cancer For BRCA testing only Dr Amol Akhade 835-845 For BRCA and HRR testing Dr Vashishth Maniar 845-855 855-900 Rebuttal 900-910 Take Home Messages for CRC and Prostate Cancer Dr Uma Dangi







High Cancer Risk Population Conference

Focused Targeting in the Era of Precision Oncology 13th & 15th August 2021 * Virtual from Mumbai



Day 2 - Sunday 15 th August 2021 - Breast and Gynecology Cancer		
1235-1240	Welcome	Dr Uma Dangi
1240-100	Sponsored Session Two - Zydus	12. 2
100-130	Sponsored Session Three - Eli Lilly Impact of CDK4/6 inhibitors in high-risk Patients with HR+/HER2- Metastatic Breast Cancer Speaker - Dr Uma Dangi	
130-135	Welcome and Introduction	Dr Uma Dangi
135-150	Interpreting Non BRCA germline mutations in familial breast & ovarian cancer for clinician	Dr Neena Bhatnagar
150-205	Screening recommendations for women with non BRCA high risk mutations	Dr T Raja
205-220	Preventive strategies for women with non BRCA high risk mutations	Dr Chetan Deshmukh
220-250	Case Based Panel Discussion Moderator - Dr Chirag Desai Panelists - Dr Seema Gulia, Dr Ullas Batra, Dr Nikhil Ghadyalpatil, Dr Vivek Agarwala & Dr Ajay Bapna	
	DEBATE – HPV vaccination should be recommended for all eligible females	
250-300	For the motion	Dr Bharat Vaswani
300-310	Against the motion	Dr Shruti Kate
310-315	Rebuttal	
315-320	Conclusions on the debate	Dr Ghanashyam Biswas
	Key International Publications from India	
320-330	Prevalence of BRCA1 and BRCA2 mutations in Ovarian Cancer in India (JCO Global Oncology)	Dr Senthil Rajappa
330-340	Guidelines for Genetic Counseling, Testing, and Management of HBOC in India (JCO Global Oncology)	Dr Hemant Malhotra
340-350	Peeking into the future - creating a road map	Dr Sudeep Gupta
	Genetic Counseling Workshop	
350-420	Mock session of Pre-test Genetic Counselling	Dr Purvish Parikh and Dr Anup Rawool
420-440	Mock Session of Post-test Genetic Counselling	Dr Veronica Arora and Team
440-450	Vote of Thanks	Dr Purvish Parikh